[
  {
    "ts": "2025-11-10T12:30:00+00:00",
    "headline": "2 Top Dividend Stocks to Buy and Hold Forever",
    "summary": "These companies have already handsomely rewarded longtime shareholders, and it's not too late to join the party.",
    "url": "https://www.fool.com/investing/2025/11/10/2-top-dividend-stocks-to-buy-and-hold-forever/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "1e8d474d-48d9-3645-a183-20a14209cfb5",
      "content": {
        "id": "1e8d474d-48d9-3645-a183-20a14209cfb5",
        "contentType": "STORY",
        "title": "2 Top Dividend Stocks to Buy and Hold Forever",
        "description": "",
        "summary": "These companies have already handsomely rewarded longtime shareholders, and it's not too late to join the party.",
        "pubDate": "2025-11-10T12:30:00Z",
        "displayTime": "2025-11-10T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/9a3064cbb3cec9a2ab64a0a5ec07b731",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "Person sitting at a desk looking at two monitors displaying stock charts.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J3SDflsLlLlzZFRW1XuA9Q--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/9a3064cbb3cec9a2ab64a0a5ec07b731.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DboOL4JJIvs2jyxg2jwOrA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/9a3064cbb3cec9a2ab64a0a5ec07b731.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/10/2-top-dividend-stocks-to-buy-and-hold-forever/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-top-dividend-stocks-buy-123000017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:00:00+00:00",
    "headline": "Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update",
    "summary": "PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian. Highlights Progressed clinical development of tecarfarin. Completed the manufacturi",
    "url": "https://finance.yahoo.com/news/cadrenal-therapeutics-reports-third-quarter-140000243.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "d01e7ae1-e010-3c2a-b000-4a688655ab41",
      "content": {
        "id": "d01e7ae1-e010-3c2a-b000-4a688655ab41",
        "contentType": "STORY",
        "title": "Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update",
        "description": "",
        "summary": "PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian. Highlights Progressed clinical development of tecarfarin. Completed the manufacturi",
        "pubDate": "2025-11-10T14:00:00Z",
        "displayTime": "2025-11-10T14:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/9eea34a5d9b040ecc7de28fefc2640df",
          "originalWidth": 673,
          "originalHeight": 193,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qyh9zHHiQRo2ymIof8sVdw--~B/aD0xOTM7dz02NzM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9eea34a5d9b040ecc7de28fefc2640df.cf.webp",
              "width": 673,
              "height": 193,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Pu7dtNV9KCy60jTfn89Qrg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9eea34a5d9b040ecc7de28fefc2640df.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cadrenal-therapeutics-reports-third-quarter-140000243.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cadrenal-therapeutics-reports-third-quarter-140000243.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CVKD"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T15:10:33+00:00",
    "headline": "How Investors May Respond To Abbott (ABT) Missing Q3 Revenue Targets While Reaffirming Outlook and Buying Back Shares",
    "summary": "In the past week, Abbott Laboratories reported its third quarter 2025 results, showing revenue up 6.9% year over year but missing Wall Street expectations and reaffirming its full-year outlook, while also completing the repurchase of more than 2.4 million shares for US$293.06 million under its ongoing buyback programs. Despite the revenue shortfall, the company’s ability to maintain its outlook and continue returning capital to shareholders through significant buybacks contributed to a...",
    "url": "https://finance.yahoo.com/news/investors-may-respond-abbott-abt-151033112.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "2d7224a4-2b09-392f-9af8-d0f1af83fbf7",
      "content": {
        "id": "2d7224a4-2b09-392f-9af8-d0f1af83fbf7",
        "contentType": "STORY",
        "title": "How Investors May Respond To Abbott (ABT) Missing Q3 Revenue Targets While Reaffirming Outlook and Buying Back Shares",
        "description": "",
        "summary": "In the past week, Abbott Laboratories reported its third quarter 2025 results, showing revenue up 6.9% year over year but missing Wall Street expectations and reaffirming its full-year outlook, while also completing the repurchase of more than 2.4 million shares for US$293.06 million under its ongoing buyback programs. Despite the revenue shortfall, the company’s ability to maintain its outlook and continue returning capital to shareholders through significant buybacks contributed to a...",
        "pubDate": "2025-11-10T15:10:33Z",
        "displayTime": "2025-11-10T15:10:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/9233d293790357e156ec19f81dd7a7d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7zJOBZ6wPnYKbKPRmWh.qQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/9233d293790357e156ec19f81dd7a7d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sc9EgsXKjWnUzlOQpxWhqQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/9233d293790357e156ec19f81dd7a7d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-may-respond-abbott-abt-151033112.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-may-respond-abbott-abt-151033112.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]